|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Loxo_Oncology
2019
2020
2021
Prevail Therapeutics
|
|
gptkbp:CEO
|
gptkb:David_A._Ricks
2017
|
|
gptkbp:clinicalTrials
|
Phase IV
Phase II
Phase III
Phase I
Numerous ongoing trials
|
|
gptkbp:dividendYield
|
1.5% (2021)
|
|
gptkbp:employees
|
35,000 (2020)
|
|
gptkbp:founded
|
gptkb:Indianapolis,_Indiana
1876
|
|
gptkbp:founder
|
gptkb:Eli_Lilly
|
|
gptkbp:globalPresence
|
Over 120 countries
|
|
gptkbp:headCoach
|
35,000 (2020)
|
|
gptkbp:headquarters
|
gptkb:Indianapolis
gptkb:United_States
gptkb:Indianapolis,_Indiana
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lilly Corporation
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:keyPeople
|
gptkb:David_A._Ricks
gptkb:A._J._C._D._de_Jongh
gptkb:Josh_Smiley
gptkb:Diana_B._McKenzie
gptkb:J._A._(Jim)_McGowan
|
|
gptkbp:market
|
$150 billion (2021)
|
|
gptkbp:partnerships
|
gptkb:Incyte_Corporation
gptkb:Boehringer_Ingelheim
gptkb:Amgen
|
|
gptkbp:patentCitation
|
Thousands of patents
|
|
gptkbp:philanthropy
|
gptkb:Lilly_Foundation
|
|
gptkbp:products
|
Insulin
Antidepressants
Cancer medications
|
|
gptkbp:R&D
|
$6 billion (2020)
|
|
gptkbp:researchFocus
|
Immunology
Neuroscience
Oncology
Diabetes
Cardiovascular diseases
|
|
gptkbp:revenue
|
$28.5 billion (2020)
|
|
gptkbp:stockSymbol
|
gptkb:LLY
|
|
gptkbp:subsidiary
|
gptkb:Elanco_Animal_Health
|
|
gptkbp:tradedOn
|
gptkb:New_York_Stock_Exchange
|
|
gptkbp:website
|
www.lilly.com
|